BETTER MEDICINE
FOR ALL.

We make drugs efficient through long-acting injectables.

Learn more

 
 
 
 

Fast expanding portfolio

Already 3 programs in Clinical

PRECLINICAL & CLINICAL DEVELOPMENT

As of february, 2020

As of June, 2021


IMPACT HEALTH

People

130+ people, all shareholders, driven to impact health

Who we are

Business model

Building a global pharma leader through long-acting injectables working with NGOs, Private Sector, and Academics

Our network

Technology

We’ve broken every barrier to enabling long-acting injectable adoption

BEPO®

Meet us

Our news

Meet us

Our news

Phase 3 data of mdc-IRM first product based on MedinCell’s technology, shows significant improvements in patients with schizophrenia

CorporateInvestors

11/15/2021

Phase 3 data of mdc-IRM, first product based on MedinCell’s […]

Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia

CorporateInvestors

08/31/2021

MedinCell announces the availability of its 2020/2021 Universal Registration Document including the Annual Financial Report

Corporate

07/28/2021

See all

 
 

Who we are

Who we are

Our strength is our people

MedinCell is operated by our talented employees who have come together from around the world to achieve our mission of Better Medicine for All.
Through purposeful innovation, we aim to improve the treatments available to patients. And we believe that everyone should have access to best-in-class medication, so we focus on making our products available regardless of local economic conditions. To ensure access, we work on both for-profit and non-profit projects, in collaboration with highly valued partners ranging from big pharmas to physicians, from biotech firms to academics and foundations. Most importantly, our partners share our values based on trust and transparency.

Who we are

Careers

CONTACT

  • This field is for validation purposes and should be left unchanged.